Contineum Therapeutics (CTNM) EBIT Margin (2023)
Contineum Therapeutics (CTNM) posted quarterly EBIT Margin of 77.87% for Q2 2023.
Powered by 
Analysis
Contineum Therapeutics (CTNM) EBIT Margin (2023) Analysis & Trends
Contineum Therapeutics' EBIT Margin history runs 1 years deep, the most recent figure standing at 77.87% for Q2 2023.
- In Q2 2023, EBIT Margin changed N/A year-over-year to 77.87%; the TTM figure through Jun 2024 stood at 77.24% (changed N/A YoY), while the FY2023 annual figure was 32.15%, changed N/A from the prior year.
- EBIT Margin for Q2 2023 stood at 77.87%.
- The five-year high for EBIT Margin was 77.87% in Q2 2023, with the low at 77.87% in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Contineum Therapeutics | 628.71 Mn | 628.71 Mn | - | - |